These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29526547)

  • 21. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteostasis of Huntingtin in Health and Disease.
    Koyuncu S; Fatima A; Gutierrez-Garcia R; Vilchez D
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28753941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational insights into missense mutations in HTT gene causing Huntington's disease and its interactome networks.
    Khan MQ; Mubeen H; Khan ZQ; Masood A; Zafar A; Wattoo JI; Nisa AU
    Ir J Med Sci; 2023 Jun; 192(3):1435-1445. PubMed ID: 35829908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.
    Southwell AL; Kordasiewicz HB; Langbehn D; Skotte NH; Parsons MP; Villanueva EB; Caron NS; Østergaard ME; Anderson LM; Xie Y; Cengio LD; Findlay-Black H; Doty CN; Fitsimmons B; Swayze EE; Seth PP; Raymond LA; Frank Bennett C; Hayden MR
    Sci Transl Med; 2018 Oct; 10(461):. PubMed ID: 30282695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional and systems biology approaches to Huntington's disease.
    González-Couto E
    Brief Funct Genomics; 2011 May; 10(3):109-14. PubMed ID: 21278081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models.
    Ehrnhoefer DE; Duennwald M; Markovic P; Wacker JL; Engemann S; Roark M; Legleiter J; Marsh JL; Thompson LM; Lindquist S; Muchowski PJ; Wanker EE
    Hum Mol Genet; 2006 Sep; 15(18):2743-51. PubMed ID: 16893904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purine Nucleotides Metabolism and Signaling in Huntington's Disease: Search for a Target for Novel Therapies.
    Tomczyk M; Glaser T; Slominska EM; Ulrich H; Smolenski RT
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Huntingtin and its role in neuronal degeneration.
    Li SH; Li XJ
    Neuroscientist; 2004 Oct; 10(5):467-75. PubMed ID: 15359012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications of the Orb2 Amyloid Structure in Huntington's Disease.
    Hervás R; Murzin AG; Si K
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32967102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphorylation of huntingtin at residue T3 is decreased in Huntington's disease and modulates mutant huntingtin protein conformation.
    Cariulo C; Azzollini L; Verani M; Martufi P; Boggio R; Chiki A; Deguire SM; Cherubini M; Gines S; Marsh JL; Conforti P; Cattaneo E; Santimone I; Squitieri F; Lashuel HA; Petricca L; Caricasole A
    Proc Natl Acad Sci U S A; 2017 Dec; 114(50):E10809-E10818. PubMed ID: 29162692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abrogation of prenucleation, transient oligomerization of the Huntingtin exon 1 protein by human profilin I.
    Ceccon A; Tugarinov V; Ghirlando R; Clore GM
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):5844-5852. PubMed ID: 32127471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Huntingtin interactions with membrane phospholipids: strategic targets for therapeutic intervention?
    Kegel-Gleason KB
    J Huntingtons Dis; 2013; 2(3):239-50. PubMed ID: 25062673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beta catenin is regulated by its subcellular distribution and mutant huntingtin status in Huntington's disease cell STHdhQ111/HdhQ111.
    Ghatak S; Raha S
    Biochem Biophys Res Commun; 2018 Sep; 503(1):359-364. PubMed ID: 29894684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A role of cellular translation regulation associated with toxic Huntingtin protein.
    Joag H; Ghatpande V; Desai M; Sarkar M; Raina A; Shinde M; Chitale R; Deo A; Bose T; Majumdar A
    Cell Mol Life Sci; 2020 Sep; 77(18):3657-3670. PubMed ID: 31796991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Pathogenesis in Huntington's Disease.
    Illarioshkin SN; Klyushnikov SA; Vigont VA; Seliverstov YA; Kaznacheyeva EV
    Biochemistry (Mosc); 2018 Sep; 83(9):1030-1039. PubMed ID: 30472941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Huntington's disease: cellular and molecular basis of pathology].
    Korzhova VV; Artamonov DN; Vlasova OL; Bezprozvannyĭ IB
    Zh Vyssh Nerv Deiat Im I P Pavlova; 2014; 64(4):359-75. PubMed ID: 25723022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of novel isoforms of huntingtin reveals a new hominid-specific exon.
    Ruzo A; Ismailoglu I; Popowski M; Haremaki T; Croft GF; Deglincerti A; Brivanlou AH
    PLoS One; 2015; 10(5):e0127687. PubMed ID: 26010866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation.
    Maglione V; Cannella M; Gradini R; Cislaghi G; Squitieri F
    Mech Ageing Dev; 2006 Feb; 127(2):213-6. PubMed ID: 16289252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.